RxDoctor Payments Data

Chukwuemeka Nwabuebo, MD

Cardiology · Macon, GANPI 1104879782

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations.

$877in general payments, 2019–2025

Across 48 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$192
  • Novartis$161
  • Kestra Medical Technology Services, Inc.$99
  • Boston Scientific$91
  • Daiichi Sankyo Inc.$54
  • Amgen$52
  • plus $228 from 8 others

What the payments were for

  • Food & beverage$874100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$877 in reported general payments places this provider in the 55th percentile of 24 cardiology providers in Georgia.

See all cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$318,206
Medicare patients
2,824
Services billed
8,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$254,039
EntrestoSacubitril/Valsartan211$169,769
FarxigaDapagliflozin Propanediol87$69,491
XareltoRivaroxaban51$31,871
Repatha SureclickEvolocumab19$13,994
BrilintaTicagrelor24$12,666
JardianceEmpagliflozin13$7,292
Repatha SyringeEvolocumab12$6,800
Potassium Chloride117$2,645
Metoprolol Succinate275$2,516
Atorvastatin Calcium269$2,223
Carvedilol308$1,881
Losartan Potassium298$1,705
Rosuvastatin Calcium182$1,691
Isosorbide Mononitrate ErIsosorbide Mononitrate169$1,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$254,039276 claims
NovartisEntresto$161$169,769211 claims
AstraZenecaFarxiga, Brilinta$34$82,157111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 24 cardiology providers in Georgia.

Other cardiology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →